Koya Medical announces positive interim results from randomized controlled study of Dayspring active compression treatment for lymphedema and venous disease.

Podimetrics partners with HealthMed to expand access to its SmartMat Program, a diabetes solution that enhances chronic care management

Podimetrics, a leader in complex diabetes care solutions, has joined forces with Alivi Health to integrate its innovative SmartMat tech into

Using Mind.Px™ test results, altered physician prescribing behavior leads to faster,more effective patient outcomes Vista, CA, May 13, 2025 (GLOBE NEWSWIRE) Mindera Health, a leader in precision medicine for dermatological conditions, today announced positive results from the completion of a randomized, prospective clinical trial (MATCH) aimed at demonstrating the clinical utility of Mind.Px™, the first

Mindera Health, a leader in precision medicine for dermatological conditions, today announced their participation in MultiPlan’s national PPO networks. Effective immediately, health plan members who access MultiPlan’s PHCS and MultiPlan Networks have access to Mindera’s Vista, CA-based laboratory that performs its proprietary test Mind.Px™. “Our vision is to realize the clinical and economic benefits of The post Mindera Health™ Signs Network Provider Agreement with MultiPlan appeared first on Mindera Health.

Mindera Health, a leader in precision medicine for dermatological conditions, today announced their participation in MultiPlan’s national PPO networks. Effective immediately, health plan members who access MultiPlan’s PHCS and MultiPlan Networks have access to Mindera’s Vista, CA-based laboratory that performs its proprietary test Mind.Px™. “Our vision is to realize the clinical and economic benefits of

Mayumana Healthcare is pleased to announce its exclusive distribution rights in the Netherlands for the Cerene® Cryotherapy Device.

Podimetrics earns a spot at No. 500 on the Inc. 5000 list for 2024, highlighting the success of its innovative approach to helping prevent diabetes-related amputations through advanced home-based monitoring and trusted patient education.

Thoraguard: A transformative digital drainage system for cardiothoracic surgery.

Thoraguard: A transformative digital drainage system for cardiothoracic surgery.

Koya CEO, Andy Doraiswamy, PhD, will share updates on the company’s progress at the Piper Sandler 36th Annual Healthcare Conference

Eirion to Present Update on Its Neuromodulator Product Candidates at The Medical Aesthetic Injectable Summit 2024October 1, 2024 – Woburn, MA – Eirion Therapeutics Inc., a biopharmaceutical company focused on developing innovative aesthetic prescription product offerings, announced today that successful results had been achieved in its Phase 1 – 2 clinical trial for the treatment of moderate to severe glabellar wrinkles using its next generation, ready-to-use liquid injectable neuromodulator AI-

Lucas is an Industry veteran who brings expertise in commercialization, operations, business development, and finance to Procyrion as it continues to focus on its DRAIN-HF pivotal IDE trial and begins preparation for US commercialization of its Aortix percutaneous mechanical circulatory support (pMCS) technology.

Discover how Koya Medical’s Dayspring® demonstrated superior efficacy and patient satisfaction in treating lower extremity lymphedema compared to pneumatic devices, as published in the Journal of Vascular Surgery.

WOBURN, Mass., July 1, 2024 /PRNewswire/ — Eirion Therapeutics Inc. announced today that the first participant has been enrolled in a Phase 1 clinical trial to evaluate the safety of the patented topical pharmaceutical ET-02 for the treatment of androgenic alopecia (age-related hair loss). This double-blind, placebo-controlled study is designed to determine the safety of ET-02 for once daily treatment over 28 days. The study is expected to recruit approximately 24 subjects at three investigatio